ESTRO 2024 - Abstract Book

S1016

Clinical - Gynaecology

ESTRO 2024

patients developed G3/4 hematological toxicities (50% G3 anemia, 50% G3 leukopenia, 60% G3/4 thrombocytopenia) out of which 1 patient had febrile neutropenia. There were no G3/4 non haematological toxicities apart from 30% lower GI toxicity.

Conclusion:

Dose dense NACT followed by BMS extended field SIB-VMAT chemoradiation is a feasible treatment option in the high risk group of cervix patients with advanced Stage IIIC2 disease. The acute haematological toxicities could be managed conservatively and were reversible with time. Longer follow up help in understanding long term toxicities and assess if the dosimetric benefits of bone marrow sparing translate to clinically meaningful outcomes.

Keywords: Bone marrow sparing, IGRT, NACT

References:

1. Green, H. M., Counsell, N., Ward, A. & McCormack, M. Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma - a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience. Clin. Oncol. 34, e281–e290 (2022).

2. Pötter, R. et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 9, 48–60 (2018).

3. Beriwal, S. et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 166–171 (2007).

4. Mell LK, Sirák I, Wei L, Tarnawski R, Mahantshetty U, Yashar CM, McHale MT, Xu R, Honerkamp-Smith G, Carmona R, Wright M, Williamson CW, Kasaová L, Li N, Kry S, Michalski J, Bosch W, Straube W, Schwarz J, Lowenstein J, Jiang SB, Saenz CC, Plaxe S, Einck J, Khorprasert C, Koonings P, Harrison T, Shi M, Mundt AJ; INTERTECC Study Group. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):536-545.

5. McCormack, M. et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br. J. Cancer 108, 2464–2469 (2013).

6. Arcadipane, F. et al. Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo Radiation: Results of the First Phase of a Prospective Phase II Trial. Cancers 12, (2020).

7. Huang, J., Gu, F., Ji, T., Zhao, J. & Li, G. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial. Radiat. Oncol. 15, 180 (2020).

8. Perry, L. J. et al. Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation. Int. J. Gynecol. Cancer 24, 564–569 (2014).

9. Vargo, J. A. et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int. J. Radiat. Oncol. Biol. Phys. 90, 1091–1098 (2014).